The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
暂无分享,去创建一个
S. Armstrong | J. Dipersio | N. Shukla | R. Stone | I. Aldoss | P. Ordentlich | M. Arellano | David S. Dickens | R. Bagley | M. Thirman | J. Perry | E. Stein | S. Shenoy | M. Meyers | H. Kantarjian | F. Perner | G. Rosen | M. Patel | G. Issa | Branko Cuglievan | G. McGeehan | Vinit Kumar | Yu Gu | Steven Smith | S. Armstrong | Ibrahim Aldoss
[1] John G Doench,et al. MEN1 mutations mediate clinical resistance to menin inhibition , 2023, Nature.
[2] S. Armstrong,et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML , 2021, Blood.
[3] M. Konopleva,et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements , 2021, Blood Cancer Journal.
[4] M. Andreeff,et al. Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.
[5] H. Xie,et al. Menin is necessary for long term maintenance of meningioma-1 driven leukemia , 2021, Leukemia.
[6] C. Bloomfield,et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A , 2020, Proceedings of the National Academy of Sciences.
[7] S. Armstrong,et al. Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.
[8] Sarah E. Dorff,et al. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis , 2020, Clinical Cancer Research.
[9] S. Armstrong,et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia , 2020, Science.
[10] K. Ross,et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.
[11] I. Kline,et al. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study , 2018, JAMA oncology.
[12] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[13] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[14] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[15] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[16] M. Sanz,et al. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. , 2014, Blood.
[17] Robert K Hills,et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Bob Löwenberg,et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[20] Jolanta Grembecka,et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.
[21] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Jeffrey S Barrett,et al. Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[24] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[25] F. Lo‐Coco,et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia , 2006, Leukemia.
[26] N. Heerema,et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.
[27] Matthew Meyerson,et al. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.
[28] Unnur Thorsteinsdottir,et al. Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia , 2001, Molecular and Cellular Biology.
[29] S. Korsmeyer,et al. Altered Hox expression and segmental identity in Mll-mutant mice , 1995, Nature.
[30] J. Michaeli,et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. , 1992, Blood.
[31] S. Armstrong,et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. , 2016, Cancer discovery.